Telix Gains FDA Approval for Pixclara in Glioma Imaging
MELBOURNE, Australia and INDIANAPOLIS, Ind. — September 14, 2026 Telix Pharmaceuticals announced that the U.S. Food and Drug Administration...
brain metastases
Advertisement
Verastem Oncology Doses First Patient in Phase 2 VS-7375 NSCLC Trial
BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...
Xodus Medical Study Validates Hot Pink Pad Performance
PITTSBURGH, Pa., July 23, 2026 Xodus Medical has announced encouraging results from a new observational clinical study demonstrating that...
GSK Wins FDA Approval for Jideytro in ROS1+ Lung Cancer
LONDON, United Kingdom, July 23, 2026 GSK plc has announced that the U.S. Food and Drug Administration (FDA) has...
GT Medical Technologies Announces GammaTile Improves Survival and Reduces Recurrence in Brain Metastases
TEMPE, Ariz., May 30, 2026 GT Medical Technologies announced positive Phase 3 results from the randomized multicenter ROADS clinical...
Advertisements
Menarini Group Reports Promising Elacestrant-Capivasertib Results in Metastatic Breast Cancer at ASCO 2026
FLORENCE, Italy and NEW YORK, May 28, 2026 Menarini Group and its wholly owned subsidiary Stemline Therapeutics have announced...
TECVAYLI Extends Survival in Relapsed Multiple Myeloma
CHICAGO, Illinois, May 29, 2026 Johnson & Johnson has reported landmark results from the pivotal Phase 3 MajesTEC-9 study,...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Dizal Highlights Promising NSCLC Therapies at ASCO 2026
May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...
Nuvalent Zidesamtinib Shows Strong NSCLC Trial Results
CAMBRIDGE, Mass., April 17, 2026 Nuvalent, Inc. has reported compelling clinical and preclinical data for its investigational drug zidesamtinib,...
Advertisement
